Program Area: Therapeutics Threat Area: COVID-1
Post# of 155613
(Total Views: 458)
Posted On: 06/03/2024 9:49:14 AM
Re: Boatbuilder #144150
Program Area: Therapeutics
Threat Area: COVID-19
Description:
Regeneron is developing a monoclonal antibody (mAb) therapeutic candidate for pre-exposure prophylaxis (PrEP) designed to neutralize all circulating virus variants, including recent Omicron subvariants. The investigational mAb binds to a conserved region of the virus, thus decreasing the risk of losing activity as the virus evolves over time and has a half-life extension to provide long-acting prevention.
Look at how much money they are throwing at this.
“Unique Impact:
Pre-exposure prophylaxis (PrEP) is a therapeutic option for preventing infection in individuals who are immune compromised or who are not protected adequately by vaccination. Currently there are no U.S. Food and Drug Administration (FDA)-approved PrEP therapeutics for COVID-19, meaning novel monoclonal antibodies could fill a critical gap in protecting individuals at high risk for COVID-19 complications.
Base Award Amount: $326,475,498.00 (August 22, 2023)
Cost Share: Yes”
https://medicalcountermeasures.gov/nextgen
Threat Area: COVID-19
Description:
Regeneron is developing a monoclonal antibody (mAb) therapeutic candidate for pre-exposure prophylaxis (PrEP) designed to neutralize all circulating virus variants, including recent Omicron subvariants. The investigational mAb binds to a conserved region of the virus, thus decreasing the risk of losing activity as the virus evolves over time and has a half-life extension to provide long-acting prevention.
Look at how much money they are throwing at this.
“Unique Impact:
Pre-exposure prophylaxis (PrEP) is a therapeutic option for preventing infection in individuals who are immune compromised or who are not protected adequately by vaccination. Currently there are no U.S. Food and Drug Administration (FDA)-approved PrEP therapeutics for COVID-19, meaning novel monoclonal antibodies could fill a critical gap in protecting individuals at high risk for COVID-19 complications.
Base Award Amount: $326,475,498.00 (August 22, 2023)
Cost Share: Yes”
https://medicalcountermeasures.gov/nextgen
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com